Pierre Lao‐Sirieix

Autolus (United Kingdom) — United Kingdom

Medicine · Health Sciences

23h-index2.2kcitations93works12.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Esophageal Cancer Research and Treatment(54), Gastric Cancer Management and Outcomes(24), Helicobacter pylori-related gastroenterology studies(17), CAR-T cell therapy research(15), Acute Lymphoblastic Leukemia research(11)

Publications93 total

Impact of chimeric antigen receptor (CAR) product cell phenotypes on clinical outcomes following treatment with obecabtagene autoleucel (obe-cel)
Blood·2025Open Access
Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel)
Blood·2025Open Access
Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/II CATULUS trial
Blood·2025
ALL-712: Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
ORAL ABSTRACT: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2025
Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Journal of Clinical Oncology·2025· 2 cited
Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)
Transplantation and Cellular Therapy·2025· 2 cited
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Genome Medicine·2024· 11 citedOpen Access
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
New England Journal of Medicine·2024· 147 citedOpen Access
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
Nature Medicine·2024· 26 citedOpen Access
Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
Blood·2024· 2 citedOpen Access
Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
Blood·2024· 1 cited
ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study
Clinical Lymphoma Myeloma & Leukemia·2024
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.
Journal of Clinical Oncology·2024· 10 cited
Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
Blood·2023· 12 cited
S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
HemaSphere·2023Open Access
FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CELL THERAPY IN RELAPSED/REFRACTORY TRBC1‐POSITIVE PERIPHERAL T‐CELL LYMPHOMA
Hematological Oncology·2023· 8 citedOpen Access
The landscape of <scp><i>BRCA1</i></scp> and <scp><i>BRCA2</i></scp> large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing
Genes Chromosomes and Cancer·2023· 5 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Rebecca C. Fitzgerald(34), Maria O’Donovan(11), Laurence Lovat(9), Wolfram Brugger(8), Marco Novelli(7), Claire Roddie(7), Karamjeet Sandhu(7), Aaron C. Logan(7), Bijal Shah(7), Martin Pulé(7), Jae H. Park(7), Paul Shaughnessy(6), Yiyun Zhang(6), Daniel J. DeAngelo(6), Elizabeth Bird‐Lieberman(5), Liam Murray(5), Sybil Varghese(5), Ken Arthur(5), Damian McManus(5), Eleni Tholouli(5)